Threshold Pharmaceuticals (NASDAQ:MTEM) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.
Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Threshold Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 22nd. ValuEngine lowered shares of Threshold Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Threshold Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.20.
Shares of Threshold Pharmaceuticals (MTEM) traded up $0.20 during mid-day trading on Friday, hitting $9.90. 213,529 shares of the stock traded hands, compared to its average volume of 99,365. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. Threshold Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $11.88. The firm has a market cap of $263.30, a price-to-earnings ratio of -5.76 and a beta of 3.13.
WARNING: “Threshold Pharmaceuticals (MTEM) Rating Increased to Strong-Buy at BidaskClub” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/22/threshold-pharmaceuticals-mtem-rating-increased-to-strong-buy-at-bidaskclub.html.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs).
Receive News & Ratings for Threshold Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.